1. Current and future immunotherapeutic approaches in Hodgkin lymphoma.
- Author
-
Bröckelmann, Paul J., Borchmann, Peter, and Engert, Andreas
- Subjects
- *
HODGKIN'S disease , *IMMUNOTHERAPY , *IMMUNOGLOBULINS , *CLINICAL drug trials , *CLINICAL trials - Abstract
Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In HL lesions, very few malignant Hodgkin and Reed-Sternberg (HRS) cells are embedded in an immunosuppressive microenvironment of reactive cells. Novel approaches such as bispecific antibodies, antibody-drug conjugates, immune-checkpoint inhibitors or adoptive cellular therapies are currently being investigated with promising results in relapsed or refractory patients. Encouraging response rates and a favorable toxicity profile have recently been reported in early phase clinical trials with antibodies blocking the programed-death receptor 1 (PD1). This review will summarize the current clinical knowledge on mechanism, safety and efficacy of the different agents and discuss potential future strategies, which are partly already investigated within clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF